Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.

For patients with benign prostatic hyperplasia (BPH), there are several options when to comes to surgical treatment. A comparison of real-world outcomes reveals significant differences in ...

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...

Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...

A surgical option which is minimally invasive and available as same-day outpatient procedure1,2,3 Following a positive Haute Autorité de Santé (HAS) assessment, a procedure code has been granted ...

Teleflex Incorporated TFX recently unveiled the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System together with real-world data presentations at the American Urological Association ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 ...

DEAR DR. ROACH: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...